filgrastim-sndz (Zarxio)
Jump to navigation
Jump to search
Introduction
Biosimilar to filgrastim FDA-approved March 2015[1]
first biosimilar product approved in the United States
Indications
- neutropenia (same of filgrastim)
- myelosuppressive chemotherapy
- acute myeloid leukemia with induction or consolidation chemotherapy
- cancer patients undergoing bone marrow transplantation
- autologous peripheral blood progenitor cell collection & therapy
- severe chronic neutropenia
More general terms
Additional terms
References
- ↑ 1.0 1.1 FDA News Release. March 6, 2015 FDA approves first biosimilar product Zarxio http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm